We offer our view of Freenome because it is part of the total ARK Venture Fund portfolio. To see the most updated portfolio, please click here.
We have known Freenome’s founders and have admired the company’s approach to earlier detection for over three years.
Our conviction in the firm is driven largely by our qualitative understanding of its go-to-market philosophy, technical due diligence into the proprietary components of its assays (both wet and dry-lab), and our quantitative, top-down work on market sizing and timing.
In short, we believe Freenome will occupy the vanguard of earlier cancer detection companies for the foreseeable future.
Unlike many sell-side analysts, we do not believe this is a zero-sum market where the success of one screening company comes to the detriment of another. The markets are too large and the unmet need is too great.
That is to say that Freenome, and others companies in the market can co-exist. In fact, we believe the combined potency of all their clinical utility data is necessary to galvanize the entire subsector’s growth.
Disclosures
We offer our view of Freenome because it is part of the total ARK Venture Fund portfolio. To see the most updated portfolio, please click here.
BEFORE INVESTING YOU SHOULD CAREFULLY CONSIDER THE FUND’S INVESTMENT OBJECTIVES, RISKS, CHARGES AND EXPENSES. THIS AND OTHER INFORMATION IS IN THE PROSPECTUS, A COPY OF WHICH MAY BE OBTAINED HERE. PLEASE READ THE PROSPECTUS CAREFULLY BEFORE YOU INVEST.
There is no assurance that the Fund will meet its investment objective. The value of your investment in the Fund, as well as the amount of return you receive on your investment in the Fund, may fluctuate significantly. You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. Therefore, you should consider carefully the following risks before investing in the Fund.
ARK Investment Management LLC is the investment adviser to the ARK Venture Fund.
Foreside Fund Services, LLC, distributor.
ARK’s statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. ARK and its clients as well as its related persons may (but do not necessarily) have financial interests in securities or issuers that are discussed. Certain of the statements contained may be statements of future expectations and other forward-looking statements that are based on ARK’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements.